Idiopathic pulmonary fibrosis (IPF) is a chronic, slowly progressive disease, but abrupt worsening without an identifiable cause, known as acute exacerbation (AE) of IPF, is not uncommon. Recently the significance of AE-IPF has become more and more evident. AE-IPF is a major cause of morbidity and mortality in patients with IPF, accounting for over half of all hospital admissions ([@bb0405]; [@bb0680]; [@bb0725]) and 40% of all deaths ([@bb0505]). Autopsy findings have also shown that AE was the most common immediate cause of death in patients with IPF ([@bb0145]). AE usually occurs later in the course of the disease ([@bb0370]; [@bb0680]; [@bb0115], [@bb0125]; [@bb0535]; [@bb0665]), but some patients experiencing AE may not have an established diagnosis of IPF and, thus, AE can be the first manifestation of an underlying preexisting IPF ([@bb0335]). Although the real nature of AE including incidence, etiology or pathogenesis is still not clear and there is no proven effective therapy, much progress has been made since the consensus statements were published in 2007, which proposed a clear definition and diagnostic criteria for the first time. The revised definition in 2016 broadened the inclusion criteria to make the diagnosis of AE-IPF more feasible in clinical practice and to help researchers clarify the nature of AE-IPF and find effective treatment. This article reviews and summarizes the present understanding of AE-IPF.

Definition {#s0010}
==========

In 2007, the National Institutes of Health--sponsored IPF Clinical Network and clinical experts proposed a consensus definition and diagnostic criteria for AE-IPF ([@bb0105]). The criteria included a clinical worsening of less than 30 days duration, the presence of new radiologic abnormalities on high-resolution computed tomography (HRCT) with bilateral ground-glass opacification/consolidation, and the exclusion of alternative etiologies. Endobronchial aspirate or bronchoalveolar lavage (BAL) was recommended to exclude potential infectious etiologies and "suspected AE-IPF" was proposed in cases of missing data ([@bb0105]). These consensus criteria were originally proposed to standardize the inclusion criteria for future research. However, performing bronchoscopy is often not clinically feasible in patients with significant hypoxemia and even when it is performed, it frequently cannot confidently exclude an underlying infection. Furthermore, the evidence demonstrated that AE-IPF had similar clinical features and prognosis compared with nonidiopathic causes of acute respiratory worsening in IPF (e.g., infection or aspiration) ([@bb0680]; [@bb0115]). Therefore, in 2016, an International Working Group published a revised definition of AE-IPF ([@bb0120]). In the current guidelines, AE-IPF is now defined by a clinically significant respiratory deterioration developing within typically less than 1 month, accompanied by new radiologic abnormalities on HRCT such as diffuse, bilateral ground-glass opacification with or without consolidation, and the absence of other obvious clinical causes like fluid overload, left heart failure, or pulmonary embolism. In the revised definition, the term "idiopathic" was omitted to allow for a broader inclusion of exacerbation, including those that may be triggered, thus enabling future researchers to better understand AE-IPF and to find effective therapies for this condition. The clinical scenarios that should be excluded, "fluid overload, left heart failure, or pulmonary embolism," are mentioned because these conditions have a different prognosis and require different therapy compared to AE-IPF. The new definition promotes discrimination between a triggered form of AE-IPF (e.g., infection, postprocedural/postoperative or drug toxicity) and an idiopathic form of AE-IPF, where no trigger is identified ([Table 1](#t0010){ref-type="table"} ).Table 1Comparison of the definition and diagnostic criteria for acute exacerbation of idiopathic pulmonary fibrosis: 2007 vs. 2016.Table 1Definition in 2007 ([@bb0105])Revised definition in 2016 ([@bb0120])Acute, clinically significant respiratory deterioration of unidentifiable causeAn acute, clinically significant respiratory deterioration characterized by evidence of new widespread alveolar abnormality*Diagnostic criteria*(1) Previous or concurrent Dx of IPF[a](#tf0010){ref-type="table-fn"}(1) Previous or concurrent Dx of IPF[a](#tf0010){ref-type="table-fn"}(2) Unexplained worsening or development of dyspnea\
•Within 30 days(2) Acute worsening or development of dyspnea\
•typically ,\<1 month duration(3) New bilateral ground-glass abnormality and/or consolidation superimposed on a background of IPF[b](#tf0015){ref-type="table-fn"}(4) No evidence of pulmonary infection by endotracheal aspirate or BAL (should include studies for routine bacterial organisms, opportunistic pathogens, and common viral pathogens)Deleted(5) Exclusion of alternative causes, including the following:\
•Left heart failure•Pulmonary embolism•Identifiable cause of acute lung injury (ALI)(Causes of ALI: sepsis, aspiration, trauma, reperfusion pulmonary edema, pulmonary contusion, fat embolization, inhalational injury, cardiopulmonary bypass, drug toxicity, acute pancreatitis, transfusion of blood products, and stem cell transplantation)(4) Deterioration not fully explained by\
•Cardiac failure or•Fluid overloadAll 5 criteriaAll 4 criteria[^1][^2][^3]

Incidence {#s0015}
=========

The reported incidence of AE is highly variable from less than 1% to almost half of patients with IPF, due to the different criteria and different patient populations studied. As shown in [Table 2](#t0015){ref-type="table"} , the incidence of AE in the placebo arm of most randomized controlled trials (RCT) was low, \> 1--5%, in contrast to 5--28% 1-year incidence of retrospective cohort studies ([@bb0120]). In earlier RCTs, AE was not predefined or listed as a secondary end point, therefore the incidence was mentioned occasionally and only as acute decompensation, acute worsening or acute respiratory failure. Most of the RCTs were performed on mild to moderate severity of IPF without significant comorbidities. In contrast, poor lung function is the most consistent risk factor of AE in the cohort studies. Therefore, the incidence of AE in the RCT may be lower than the incidence in general patient population due to exclusion of IPF patients with more severe disease. Further, the definition of AE is important; in a *post hoc* analysis of the Sildenafil Trial of Exercise Performance in Idiopathic Pulmonary Fibrosis (STEP-IPF) ([@bb0800]), definite AE-IPF occurred in 4 per 100 patient-years, but combining definite and suspected AE-IPF increased the incidence to 20 per 100 patient-years ([@bb0115]). The annual rate of AE in a registry-based US study was even lower, 0.13 per patient-year ([@bb0195]).Table 2Incidence rate of acute exacerbation of idiopathic pulmonary fibrosis reported in randomized clinical trials.Table 2Drug (reference)GroupNo. of patientsAge yearAE (%)Non-smoker (%)FVCDLPeriodCriteria*Pirfenidone*Azuma ([@bb0060])Placebo3564.314.2678.45.79 mJRSTx726401181.657.6Taniguchi ([@bb0710])Placebo10464.73.820.279.155.252 wJRSTx-low-dose5563.93.621.876.253.6Tx-high dose10865.43.720.477.352.1CAPACITY-1 ([@bb0515])Placebo17465.71.72976.246.177 wIPFnet + PaO~2~Tx-low dose87681.13176.447.2Tx-high dose17466.31.13274.546.4CAPACITY-2 ([@bb0515])Placebo173670.63773.147.477 wIPFnet + PaO~2~Tx17166.81.23574.947.8*Nintedanib*TOMORROW ([@bb0600])Placebo8564.815.7NA77.67552 wTx8565.42.4NA78.178.3INPULSIS-1 ([@bb0605])Placebo204675.425804752 wIPFnetTx309676.1238048INPULSIS-2 ([@bb0605])Placebo219679.632784652 wIPFnetTx329663.6318047*N-acetylcysteine*IFIGENIA ([@bb0155])Placebo64.46413175741 YResp. failureTx64.4626398079*Interferon gamma-1b*INSPIRE ([@bb0345])Placebo27565.95.53173.147.3\
64 wARFTx551664.52872.247.4*Bosentan*BUILD-1 ([@bb0340])Placebo8365.13.6NA69.541.412 mAcute decompensationTx7165.31.4NA65.942.3BUILD-3 ([@bb0350])Placebo20963.22.932.173.147.920 mAE (not defined)TX40763.84.738.174.947.7*Imatinib*([@bb0150])Placebo6067.81.73665.639.396 wAcute worseningTx59668.42864.439.8*Sildenafil*STEP-IPF ([@bb0800])Placebo9168.242458.726.712 wIPFnetTX89702245525.8[^4][^5][^6][^7][^8][^9][^10][^11][^12][^13][^14][^15][^16][^17][^18][^19][^20][^21][^22][^23]

Risk Factors {#s0020}
============

Poor Lung Function, Advanced Disease {#s0025}
------------------------------------

Advanced disease with low lung function is the most consistent risk factor of AE-IPF in the majority of the studies, including low forced vital capacity (FVC) ([@bb0370]; [@bb0680]; [@bb0115], [@bb0125]; [@bb0535]; [@bb0665]), low diffusion capacity for carbon monoxide (DLco) ([@bb0455]; [@bb0115]; [@bb0665]), low total lung capacity (TLC) ([@bb0455]; [@bb0570]), lower 6-min walking distance ([@bb0115]), impaired baseline oxygenation ([@bb0115], [@bb0125]; [@bb0375]), a recent decline in FVC ([@bb0370], [@bb0375]; [@bb0595]), and an increase in dyspnea ([@bb0370]; [@bb0115]). There are some who suggest that advanced disease itself may not increase the real incidence, but increases the chance for recognition due to more symptoms and signs in the patients with already poor physiologic reserve. However, this higher occurrence of AE in the patients with lower lung function was seen not only in cohort studies, but has also been observed in RCTs. In the INPULSIS trials, where AE-IPF was a secondary end point, the 1-year-incidence of AE in patients with a FVC of \< 70% predicted was 14.9%, but in those with an FVC \> 70% predicted the incidence was 3.3% ([@bb0130]). Also a meta-analysis of six RCTs showed that AE occurred less frequently in trials excluding severe disease (28.2 vs. 122.9 AE/1000 patient years^--1^, *P* \< 0.0001) ([@bb0055]). In the INPULSIS-ON study (the open-label extension of the INPULSIS trials), a *post hoc* subgroup analysis demonstrated that the progression of disease and fatal events were more frequent in the subgroup of patients with more severe disease (FVC ≤ 50% at the start of the extension phase) than in patients with a less severe disease, although the difference was not statistically significant ([@bb0790]).

Prior History of Acute Exacerbation {#s0030}
-----------------------------------

Acute exacerbation was reported to be more common in the patients with previous history of AE ([@bb0405]; [@bb0305]; [@bb0595]; [@bb0655]).

Comorbidity {#s0035}
-----------

Coexisting pulmonary hypertension ([@bb0310]; [@bb0570]) and coronary artery disease ([@bb0115]) have been reported as a risk factors for AE-IPF.

Higher Serum Krebs von Lungen-6 (KL-6) Level {#s0040}
--------------------------------------------

Elevated serum levels of KL-6 at baseline have been associated with an increased risk for AE-IPF, after adjustment for clinical features including vital capacity (VC) ([@bb0535]). Sato et al. reported that on multivariate analysis, KL-6 along with surgical procedures, history of AE, %VC, and male sex were the independent risk factors for the occurrence of AE in 1235 cases with lung cancer and IPF ([@bb0655]). Qui et al. reported that higher serum KL-6, poor pulmonary function, mechanical procedures, and secondary pulmonary hypertension were associated with increased risks of AE-IPF on meta-analysis of seven studies ([@bb0570]).

High Body Mass Index (BMI) {#s0045}
--------------------------

Kondoh et al. reported that high BMI was a risk factor for AE ([@bb0370]), but there are some conflicting data ([@bb0570]).

Smoking {#s0050}
-------

There is controversy on the effect of smoking and AE in IPF. [@bb0680] and Kishaba et al. reported an increased incidence of AE in never-smoking IPF patients (50% in never-smokers vs. 18.2% in ever-smokers, *P* \< 0.0001). However, some studies have observed a higher risk in former smokers ([@bb0535]; [@bb0125]).

Ethnic Differences {#s0055}
------------------

It has been suggested that the East Asian patient population may be at greater risk for AE compared with patients of other races ([@bb0620]). However, in the INPULSIS study, the incidence of AE in Asian patients was similar to whites, in both the placebo and nintedanib groups. Among Asians, AE developed in 4.9% of the nintedanib group and 7.6% of the placebo group. In Caucasian patients, AE was reported in 3.6% of the nintedanib group and 6.9% of the placebo group ([@bb0715]).

Etiology and Triggering Factors {#s0060}
===============================

In most cases of AE-IPF, the cause or triggering factor is not certain. But in some cases, AE develops after a preceding event, such as following surgery or after administration of a pulmonary-toxic medication. The following are triggering factors that have been reported in AE-IPF.

Infection {#s0065}
---------

Fever, "flu-like" symptoms and neutrophilia in BAL fluid specimens implicate an underlying infectious etiology, especially viral. Many studies report that AE occurred more frequently in winter and spring months ([@bb0675]; [@bb0130]; [@bb0530]) and in patients taking immunosuppressive medications. One large study of 220 patients with ILD (100 cases of IPF, 120 cases of non-IPF) showed that 20% of patients were diagnosed with an infection in the setting of an acute respiratory worsening ([@bb9000]). Although these accompanying clinical features suggest an infectious etiology, efforts to prove infection in AE-IPF have not been successful. [@bb0780] tested BAL fluid and serum from patients with AE-IPF, stable IPF, and those with acute lung injury (ALI) without IPF for viral nucleic acid using multiplex polymerase chain reaction testing, pan-viral microarray, and high-throughput cDNA sequencing. Of the 43 patients with AE-IPF, only four had the evidence of a common respiratory virus (parainfluenza, rhinovirus \[*n* = 2\], and coronavirus). No viruses were detected in the stable IPF patients. Additional pan-viral microarrays revealed evidence of nonrespiratory viruses in 15 patients with AE-IPF: herpes simplex virus, Epstein--Barr virus, and torque teno virus (TTV) (*n*  = 12). TTV was found in similar percentages (24%) of patients with ALI. The clinical significance of TTV remains to be determined. Konishi et al. also failed to identify any gene transcription profiles that would be expected in a viral infection, in both patients with AE-IPF and stable IPF ([@bb0385]). In a prospective study of *C. pneumoniae* infection triggering AE-IPF, only two patients had an antibody response ([@bb0740]), suggesting that *Chlamydophila* is an unlikely trigger for AE-IPF.

Although existing data do not support the role of infection/viruses in all, or even in a majority of cases of AE, it is still possible that infection triggers AE. Due to the relative insidious onset of AE (up to 30 days), any triggering viruses would likely no longer be detectable by the time of clinical presentation of AE, leaving only the acute lung injury pattern with aggravation or acceleration of the underlying interstitial lung disease (ILD). Also, the detection of infection is difficult even with invasive procedures. Autopsy studies found that 28.8% of patients with AE-IPF had a bronchopneumonia (fungal: 13.5%; cytomegalovirus: 11.5%; and bacterial: 9.6%) identified postmortem, but were clinically unsuspected, highlighting difficulties in diagnosing infection in this setting ([@bb0525]). A recent study of 119 bronchoscopies performed in 106 ILD patients presenting with acute respiratory failure showed that only 16 of 119 (13%) revealed a potential cause of respiratory worsening ([@bb0045]). Furthermore, identifying infection has not yet been demonstrated to affect outcomes, despite the treatment of microorganisms identified by BAL fluid, a fatal outcome eventually occurred and mortality remained high ([@bb0075]).

Recent studies on the human lung microbiome have shown that changes in number and composition may play an important role in the pathogenesis and progression of lung diseases, including IPF ([@bb0245]; [@bb0480]). Integrated analysis of the host transcriptome and microbial signatures demonstrate an interaction between host and environment in IPF. The response to an altered and more abundant microbiome remains during longitudinal follow-up, suggesting that the bacterial communities of the lower airways may act as a persistent stimulus for repetitive alveolar injury in IPF ([@bb0490]). In the BAL fluid of AE-IPF, bacterial burden was also increased compared to stable IPF, with an increase in *Campylobacter* sp. and *Stenotrophomonas* sp., as well as a significant decrease in *Veillonella* sp. compared to stable IPF ([@bb0485]). These findings suggest that infection may be an important trigger of AE-IPF even though the presence of a microbial organism is not detected.

Gastroesophageal Reflux (GER) and Microaspiration {#s0070}
-------------------------------------------------

Although an increasing number of studies document a high prevalence of GERD (up to 87%) in patients with IPF ([@bb0575]; [@bb0415]), there is no direct evidence for causal relationship. Increased pepsin levels in the BAL fluid of the patients with AE-IPF ([@bb0420]; [@bb0685]) suggested that GER with aspiration of gastric acid and other nonacid components may trigger the episode of AE. Animal studies have demonstrated that the instillation of acid or gastric juice provoked the diffuse alveolar damage pattern, which is the pathologic pattern of AE-IPF. Further, Lee et al. reported that in the placebo arm of three RCTs (STEP-IPF, ACE-IPF and PANTHER-IPF), patients taking anti-acid therapy at baseline had a slower decline in FVC (over 30-weeks of --0.06 L vs. --0.12 L, *P* = 0.05) and fewer AE (no events versus nine events, *P* \< 0.01) during the study period ([@bb0425]). Recent studies reported that proton pump inhibitor (PPI) possess anti-inflammatory and anti-fibrotic activities by directly suppressing proinflammatory cytokines, profibrotic proteins, and proliferation of lung fibroblasts ([@bb0230]).

However, the association is controversial. A small cohort study of *H. pylori* in lung tissue reported no relevant differences in AE events between the gastroesophageal reflux disease (GERD) and non-GERD IPF subgroups ([@bb0395]). Also, the recent pooled INPULSIS data showed that the frequency of investigator-reported AE was higher (11.7%) among the patients who were on antacid medication at baseline in the placebo group, compared to no antacid in placebo group (5.0%), and no difference in AE rates on or off antacids in nintedanib group (4.9% vs. 4.8%, respectively) ([@bb0135]).

In the study of asymmetric IPF, the rate of GER was higher in 32 patients with asymmetric IPF (62.5%) than in 64 matched symmetric IPF (31.3%, *P* = 0.006) and similarly AE was significantly more frequent in asymmetric IPF (46.9% vs. 17.2%, *P* = 0.004). In 10 of 15 patients who developed AE (67%), the ground glass opacities (GGO) was virtually unilateral, occurring in the most affected lung by IPF (in most cases, right side). This suggests that loco-regional factors, including GER, may be responsible for both the asymmetry and the occurrence of AE ([@bb0720]). However, later, Callahan reported that no statistically significant difference in the number of AE (43% vs. 39%, *P* = 0.824) and GER (both groups 50%) was observed in 14 asymmetric cases of IPF compared to 28 controls ([@bb0085]). These data should be interpreted with caution; the numbers of subjects were smaller and the incidence of AE in symmetric IPF group seemed to be relatively high (39%) compared to most other reports. Only three of 14 patients in the asymmetric group had strictly unilateral involvement and 9 of 14 patients had left lung dominant disease.

Last, WRAP-IPF ([@bb0590]), a phase 2 prospective un-blinded RCT of laparoscopic antireflux surgery in patients with IPF and abnormal acid GER showed that AE (3% vs. 16%, *P* = 0.19), respiratory-related hospitalization (7% vs. 21%, *P* = 0.25) and death (3% vs. 13%, *P* = 0.13) was less common in the surgery group, but did not meet statistical significance. Considering the potential side effects associated with long term PPI use ([@bb0200]) and an increased risk of infections, including pulmonary infections, observed in many reports ([@bb0400]; [@bb0135]), a well-designed, prospective RCT is required to understand the relationship between GER and IPF and also to evaluate the safety and therapeutic efficacy of PPIs/antacids and antireflux surgery for IPF. A recent single-center, double blind RCT of omeprazole in IPF ([@bb0175]) suggested some feasibility for a larger RCT, although the question of a gold standard method for the diagnosis of GER, especially for a large clinical RCT, remains.

Mechanical Procedures {#s0075}
---------------------

AE-IPF development after the pulmonary resection due to lung cancer has been reported to occur in 3--32% ([@bb0770]; [@bb0630]; [@bb0690]; [@bb0680]; [@bb0460]). AE has been reported to occur after nonpulmonary surgery ([@bb0680]; [@bb0225]; [@bb0095]) and surgical lung biopsy, although the incidence rate is low ([@bb0365]; [@bb0565]; [@bb0070]; [@bb0650]). Cases of AE-IPF were also reported following BAL ([@bb0260]; [@bb0335]; [@bb0635]) and cryobiopsy ([@bb0090]; [@bb0730]; [@bb0160]). The mechanism of AE in this setting is not certain, but may be due to increased susceptibility of additional mechanical stress on an already fibrotic and noncompliant IPF lung.

Drugs {#s0080}
-----

AE-IPF has also been observed in patients receiving chemotherapy for lung cancer, or following radiotherapy ([@bb0630]; [@bb0235]; [@bb0775]). Minegishi et al. reported that AE developed after chemotherapy (single drug: 20%, multiple drugs: 42.9%) and radiation therapy (16.7%), but also occurred in 20% of the patients who received only supportive care without any therapy ([@bb0450]).

Air Pollution {#s0085}
-------------

Exposure to increased ozone and nitrogen dioxide levels in ambient air has been reported to be associated with AE-IPF ([@bb0305]).

Pathology {#s0090}
=========

The pathological findings of AE-IPF comprise underlying usual interstitial pneumonia (UIP) with three types of acute lung injury pattern; diffuse alveolar damage (DAD), organizing pneumonia (OP) with or without evidence of organizing DAD, or extensive fibroblastic foci ([@bb0100]). The patients with OP pattern and extensive fibroblastic foci appear to have better prognosis ([@bb0100]) and Akira et al. reported that the patients with these OP or extensive fibroblastic foci had a peripheral type of GGO on HRCT. The findings on surgical lung biopsies are different from autopsy specimens ([@bb0525]). In autopsy specimens, UIP was seen in all, DAD in 78.8%, pulmonary hemorrhage in 28.8%, thromboembolism in 17.8% and lung cancer in 11.5%. In addition, 28.8% showed bronchopneumonia, but OP without DAD was found in only 1.9%, which might be related to better prognosis with an OP pattern and consequently seen less frequent at autopsy. Recently Balestero et al. performed morphometric analysis on explanted lung specimens of 41 patients with IPF, including 11 AE-IPF, and compared pathologic findings with clinical disease progression. Prominent cellular inflammatory infiltrates with a number of both innate (neutrophil, macrophage) and adaptive inflammatory infiltrate (CD4, CD 8, B cell) was significantly higher in the acute exacerbators and rapid progressors compared to the slow progressors. The slow progressors who developed AE showed a more marked increase in overall inflammation (CD45 +) than the slow progressors who did not develop AE. Indeed, the degree of inflammation in the rapid progressors who did not exacerbate was similar to that in the acute exacerbator. Interestingly, DAD, that is considered a characteristic feature of AE, was also found to the same extent in rapid progressors who did not exacerbate ([@bb0065]).

Biomarkers {#s0095}
==========

Many blood biomarkers have been reported to have a role in predicting the clinical course and outcomes of AE-ILD, including lactate dehydrogenase: LDH, C-reactive protein: CRP, KL-6, surfactant protein-D: SP-D ([@bb0455]; [@bb0355]; [@bb0675]; [@bb0680]), pro-calcitonin ([@bb0165]), circulating fibrocytes ([@bb0465]), interleukin-7 ([@bb0695]), anti-heat shock protein 70 autoantibodies ([@bb0320]; [@bb0315]), alpha-defensin ([@bb0640]), ST-2 and decorin ([@bb0510]), syndecan ([@bb0660]). However, none of them have been properly validated in prospective studies and biomarkers currently do not impact clinical decision making in AE ([@bb0380]). KL-6 is a mucin-like glycoprotein, which is mainly expressed in type II pneumocytes and bronchial epithelial cells ([@bb0360]). It is detected in regenerating type II cells ([@bb0360]) and has been widely used in Japan as a serum marker of predicting the disease course and development of AE-IPF ([@bb0535]). Recently, Maher et al. found that SP-D and CA19-9 were the most discriminatory biomarkers in 106 patients with IPF and validated in 206 patients enrolled in a prospective, multicenter, observational cohort study of incident cases of fibrotic interstitial lung disease (PROFILE) study. Baseline values of SP-D (46.6 ng mL^--1^ vs. 34.6 ng mL^--1^, *P* = .0.0018) and CA19-9 (53.7 UmL^--1^ vs. 22.2 UmL^--1^; *P* \< 0.0001) were significantly higher in patients with progressive disease than in patients with stable disease, and rising concentrations of CA-125 over 3 months were associated with increased risk of mortality (HR 2.542, 95% CI: 1.493--4.328, *P* = 0.00059), but the association with AE is unknown ([@bb0440]).

Treatment {#s0100}
=========

There is no proven, effective treatment for AE-IPF. In clinical practice, high-dose corticosteroids are widely used and current international guidelines have a weak recommendation for its use, solely based on the high mortality of AE-IPF and anecdotal reports of benefit ([@bb0580]). However, there are no controlled trial data supporting the efficacy or safety of corticosteroids in AE-IPF. Some studies have reported a better survival with combination immunosuppressive agents like cyclophosphamide (CTX), cyclosporine-A (CsA), or tacrolimus and auto-antibody reduction therapy with rituximab combined with therapeutic plasma exchange and intravenous immunoglobulin ([@bb0170]). Other innovative procedures, such as polymyxin B-immobilized fiber column direct hemoperfusion (PMX-DHP) and recombinant human thrombomodulin (rh TM), have been tried, mostly in Japan. However, these studies are often small, retrospective observational cohort studies or controlled studies compared to historical and/or parallel untreated controls, which have obvious or hidden confounding factors, like selection bias or differences in general supportive care.

The results of therapeutic trials in AE-IPF are summarized in [Table 3](#t0020){ref-type="table"} .Table 3Summary of treatment studies in acute exacerbation of idiopathic pulmonary fibrosis.Table 3ReferencesDesignPeriodNo.Tx.30 d-SR (%)3 m-SR (%)In-hospital SR (%)Median SRRemark*Corticosteroid (CS) monotherapy*[@bb0025]R. S.17CS47.1[@bb0705]R. S.140Mean: 79 ± 99 d[@bb0560]R. S.1996--20025CS2020Survived 30 m[@bb0335]R. S.1990--20036CS18.7[@bb0680]R. S.1990--200967CS43[@bb0690]R. S.2000--20069CS100Postsurgery AE. 3 year-SR: 42%[@bb0755]Pro. S.2010--20126CS17[@bb0285]Cont. R. S.1990--19996CS (as control group)83331 year-SR: 11.1%[@bb0625]Cont. S.1994--200411CS (as control group)825560 d[@bb0270]Cont. R. S.2001--201010CS (as control group)60201038 d*Corticosteroid (CS) + cyclophosphamide (CTX)*[@bb0035]R. S.2001--20025CS + CTX20201 year-SR: 20%[@bb0495]R. S.2005--10CS + CTX10055 (suspected AE:100)1 year-SR of AE + suspected AE: 33%[@bb0675]R. S.2002--20099CS + CTX100In-hospital SR all 27 patients:73%[c](#tf0030){ref-type="table-fn"}[@bb0520]R. S.2009--201311CS + CTX73911 year-SR: 55%[@bb0030]R. S.1994--200458CS + CTX56.9[@bb0700]R. S.2003--200913CS ± CTX ± PMX[b](#tf0025){ref-type="table-fn"}31[@bb0275]Cont. S[a](#tf0020){ref-type="table-fn"}2004--201726CS + CTX ± PMX[b](#tf0025){ref-type="table-fn"}76.9Propensity score matched controlled study26CS ± PMX[b](#tf0025){ref-type="table-fn"}84.6*Corticosteroid + CTX or cyclosporine-A(CsA)*[@bb0275]R. S.2004--2017102CS (100) + CTX/CsA ± PMX[b](#tf0025){ref-type="table-fn"}64.71 year-SR: 40.6%[@bb0550]R. S.1994--200428CS + CTX/CsA140.9 m[@bb0795]R.S1998--200411CS + CTX/CsA45.530 d[@bb0680]R. S.1990--200990CS + CTX/CsA40502.2 m[@bb0205]R. S.1998--200660CS + CTX/CsA1 year-SR: 18.3%[@bb0020]Pro. Cont.2014--201411 (4 NSIP)CS + CTX/CsA (control group)561014 d*Cyclosporin-A (CsA)*[@bb0285]Cont. R. S.1990--19997CS + CsA85.771.41 year-SR: 71.4%6CS83.333.31 year-SR;11.1%[@bb0265]Cont. R. S.1997--20049CS + CsA679.9 m1 year-SR: 22.2%35CS (historical control)2.91.7 m1 year-SR: 2.9%[@bb0625]Cont. R. S.1994--200411CS + CsA9180285 d11CS825560 d[@bb0325]Cont. S.2009--201120CS + CsA ± LMWH53%Control group for rhTM[@bb0050]R. database2010--20147605CS74.7384CS + CsA76.1*Tacrolimus*[@bb0270]Cont. R.2001--20105CS + Tacro80808092 dAE: none10CS60201038 dAE: 40%*Autoantibody reduction therapy (Therapeutic plasma exchange: TPE) + Rituximab + IVIG (IV Immunoglobulin)*[@bb0170]Pros. historical control\
2 centers2011--201311CS + TPE72.745.560 d: 55 ± 15Improved gas exchange and symptom. 1 year-SR:46 ± 15%2009--201121CS60 d: 20 ± 9Medical archival record system, no 1 year-SR*Sivelestat*[@bb0500]10CS ± Sivel\
All on MV6 m-SR: 40Improved PF ratio*Polymyxin B-immobilized fiber column direct hemoperfusion (PMX-DHP)*[@bb0670]Pro. Open label6CS + PMX + MV6767[@bb0010]Pros. Pilot, S.20CS + PMX + MV703535[@bb0250]R. S.2006--20099CS + PMX ± CsA55.533.3[@bb0695]R. S.2006--200919CS + PMX47.426.322 dIL-7, P/F: improved[@bb0015]R. Multi2004--200873CS + PMX ± anti-coagulant70.134.5[@bb0540]R. S.2009--20119CS + PMX ± CTX/CsA66.7[@bb0180]Cont. R. S.2009--201314CS + PMX ± CTX/CsA + sivel61.31 year-SR: 48.2%. Better P/F ratio1997--201217CS ± CTX/CsA ± sivel651 year-SR: 5.9%[@bb0545]Cont. R. S.2008--201427CS + PMX ± CTX/CsA)70.463192 d1 year-SR: 41.7% (*P* = 0.04)2006--200823CS ± CTX/CsA47.926.129 d1 year-SR: 9.8%[@bb0280]Cont. R. S.2007--20155CS + PMX ± CTX/CsA/Tacro ± Sivel40Better 90 d-SR in other type of IIP2002--20077CS ± CTX/CsA/Tacro ± Sivel42.9[@bb0210]Cont. R. S.2006--201510CS + PMX ± CTX/CsA/TacroOverall SR: 33%. [a](#tf0020){ref-type="table-fn"}Early induction was better14CS ± CTX/CsA/Tacro55Overall SR: 33%*Human recombinant Thrombomodulin (rhTM)*[@bb0755]Pro. historical control2010--201220CS + rhTM + NIV/MV67556CS + NIV/MV17[@bb0290]R. Control. S.2006--201316CS + rhTM ± CsA ± LMWH69165 d25CS ± CsA ± LMWH4053 d[@bb0325]Pros. S. Historical Control2009--201120CS + rhTM ± CsA + LMWH702007--200920CS ± CsA + LMWH35[@bb0020]Pros. S. Cont. (at different time)2012--201311 (2 NSIP)CS + rhTM ± CSA/CTX +8264Not reached2014--11 (4 NSIP)CS ± CSA/CTX561014 d[@bb0255]Pro. S. Historical Control2012--201410CS + rhTM7060153 d1 year-SR: 40%2009--201213CS ± CTX/CsA ± PMX ± Sievel541548 d1 year-SR: 8%[@bb0645]Cont. S.2011--201645CS + rhTM ± CSA67167 d2006--201135CS ± CSA ± LMWH3735 d[@bb0040]Pro. multi. historical Control2014--201639 IIP (12IPF)CS + rhTM ± AZP/CTX/CSA ± Pirf ± PMX6747.5 dPropensity score matched control.2011--201361 IIP (26 IPF)CS ± AZP/CTX/CSA ± Pirf/Nin ± PMX47.566.7 dNo data on IPF*Antibiotics*[@bb0330]Cont. R. S.2012--201638CS + Azithro60 d\
SR: 742005--201247CS + fluoroquinolone ± PMX60 d\
SR: 30[@bb0530]R. database2010--2013209MV + CS ± CTX, cotrimox, azithro44.624.621 dJapanese Diagnosis Procedure Combination database*Pirfenidone*[@bb0215]Cont. R. S.2008--201520Pirf ± CS ± rhTM55*P* = 0.0422008--201527CS ± rhTM34*Supportive care + antibiotics*[@bb0555]Pro. multi. open label2007--201317No CS, Supportive care + antibiotics52451.73 m[^24][^25][^26][^27]

Corticosteroids {#s0105}
---------------

Although corticosteroids have been administered to most patients with AE-IPF, actual reported data are limited. There are no placebo controlled studies for corticosteroid use. In 4 controlled studies, a corticosteroid group was used as a control group and the reported outcomes are shown in [Table 3](#t0020){ref-type="table"} ([@bb0285]; [@bb0625]; [@bb0270]; [@bb0750]). Other studies have been small, retrospective and in a single center. The reported survival rate is highly variable with a 3-month-survival rate ranging from 18.7% to 100% (100% was the result of acute exacerbation developed after lung resection in nine patients with cancer), but mainly around 50%. The largest study was by Song et al. who reported an in-hospital survival rate of 43.3% in 67 patients treated with variable doses of corticosteroid mono-therapy ([@bb0680]). The median survival reported in two other studies was 38 days and 60 days ([@bb0270]; [@bb0625]).

Cyclophosphamide (CTX) {#s0110}
----------------------

There are no data of cyclophosphamide (CTX) mono-therapy. In all studies, CTX was given with corticosteroids. Ambrosini et al. reported that the 3 month-survival rate was only 20%, but they had only five study subjects ([@bb0035]). In the study of Morawiec et al., 55% of patients with AE-IPF survived at 3 months, but in suspected AE-IPF who had slightly delayed onset, all seven patients survived ([@bb0495]). Another study reported that all nine patients treated with CTX were discharged and the median survival period was 4.2 months ([@bb0675]). Novelli et al. reported that the 3 month-survival rate was 73% and 55% survived more than 1 year ([@bb0520]). In other studies, either CTX or cyclosporine-A (CsA) was administered with corticosteroids. The reported 3 month-survival rate of corticosteroids + either CTX or CsA was 10--40%, except in the study by Hozumi et al. Hozumi et al. analyzed 102 patients with AE-IPF who were treated with corticosteroids + either CTX or CsA. Their 3 month-survival rate was 64.7%. They also evaluated the efficacy of corticosteroid mono-therapy and corticosteroids + CTX separately using a propensity score-matched method. They compared the outcomes of 26 patients treated with corticosteroids + CTX to that of 26 patients treated with corticosteroid mono-therapy, matched using propensity scores. There was no difference in the 3 month-survival rate between the two groups; corticosteroids + CTX group: 76.9% vs. corticosteroid control group: 84.6%.

Cyclosporin-A (CsA) {#s0115}
-------------------

The majority of studies on CsA have been controlled studies, however they were all retrospective using a historical control group. As shown in [Table 3](#t0020){ref-type="table"}, the three month-survival of the CsA group was higher than that of a matched corticosteroid control group (71.4% vs. 33.3% in Inase et al., 67% vs. 2.9% in Homma et al., and 80% vs. 55% in Sakamoto et al.) ([@bb0285]; [@bb0265]; [@bb0625]). But in the study of Kataoka et al., where the CsA was a control group for rhTM group, the 3 month-survival was 35%, lower than 70% observed in the rhTM group ([@bb0325]). Aso et al. compared the outcome of CsA therapy using the Diagnosis Procedure Combination Database in Japan. The in-hospital survival rate of 384 patients treated with CsA was 74.7%, similar to the survival rate of 7605 patients in a corticosteroid control group (76.1%) ([@bb0050]).

Tacrolimus {#s0120}
----------

Tacrolimus is an immunosuppressant used mainly to prevent rejection in solid organ transplantation and in the treatment of connective tissue diseases. Tacrolimus inhibits T cell activation and interleukin-2 (IL-2) and other helper T cell cytokines, similar to CsA, but more potent. It also prevents immune activation by inhibiting nuclear factor κB (NF-κB) and TGF-β-induced collagen deposition. Horita et al. compared the effect of tacrolimus in five patients with AE-IPF to a historical control group (10 patients on corticosteroids only). The 3 month-survival rate in the tacrolimus group was 80% with a median survival of 92 days, which was higher than the control group (10%, 38 days). No surviving patients from the tacrolimus group had a reexacerbation for at least 6 months after their initial AE, whereas four of the nontacrolimus group patients died from reexacerbation between 1 and 4.5 months after their initial AE ([@bb0270]).

Autoantibody Reduction Therapy {#s0125}
------------------------------

Recent evidence has shown that immune inflammation and auto-antibodies may be involved in IPF progression and AE-IPF ([@bb0065]). Treatments that reduce autoantibodies might be of benefit in a subset of patients with IPF ([@bb0315]; [@bb0190]). Therefore, autoantibody reduction therapy, including therapeutic plasma exchanges (TPE), corticosteroid pulse, rituximab followed by intravenous immunoglobulin was studied in 11 critically ill patients with AE-IPF. Nine patients (82%) showed improvement in pulmonary gas exchange compared to only one among 20 patients in a historical control group ([@bb0170]). The 3 month-survival rate of the trial subjects was 45.5% and the 1-year survival was 46 ± 15% vs. 0% among historical controls. As a result of this study, additional trials are ongoing and listed on Clinicaltrials.gov (Therapeutic Plasma Exchange, Rituximab and IV Ig for Severe Acute Exacerbation of IPF Admitted in ICU (EXCHANGE-IPF) NCT03584802 Open-randomized controlled and Phase 2 Autoantibody Reduction for Acute Exacerbations of Idiopathic Pulmonary Fibrosis (STRIVE-IPF) NCT03286556).

Sivelestat {#s0130}
----------

Due to the implication of neutrophils in AE-IPF, the efficacy of a neutrophil elastase inhibitor, sivelestat, in combination with corticosteroids was examined in 10 mechanically ventilated patients with AE-IPF. Four of 10 patients survived to day 180 and in the survivors, the PaO~2~/FiO~2~ (arterial oxygen tension/fraction of inspired oxygen), C-reactive protein, and positive end-expiratory pressure (PEEP) levels were improved ([@bb0500]).

Polymyxin B-Immobilized Fiber Column Direct Hemoperfusion (PMX-DHP) {#s0135}
-------------------------------------------------------------------

PMX-DHP was originally developed for the removal of endotoxins from gram-negative bacteria based on the potential of columns to absorb endotoxins, plasma proinflammatory, profibrotic and proangiogenic cytokines, reactive oxygen species, and activated neutrophils. The use of PMX-DHP columns has been studied in patients with acute respiratory distress syndrome (ARDS) and improvements in oxygenation have been observed with therapy ([@bb0140]). After the open label pilot trial of PMX-DHP in six patients with AE-IPF demonstrated a 3 month-survival rate of 67% ([@bb0670]), several more retrospective cohort studies were performed and reported 3 month survival rates between 27--67% ([Table 3](#t0020){ref-type="table"}). The biggest study was by Abe et al., who performed PMX-DHP on 160 patients with interstitial pneumonia including AE-IPF (73 patients) and other types of interstitial pneumonia, such as nonspecific interstitial pneumonia (NSIP) or organizing pneumonia (OP), which might respond to high doses of corticosteroids. All patients had been given corticosteroids. Therefore, the response may not be solely due to PMX-DHP. In this study, the 3 month-survival of AE-IPF was 34.5% ([@bb0015]).

There have been four controlled trials using PMX-DHP. Two studies were performed only in AE-IPF patients and both studies reported a better survival in PMX-DHP group. In Enomoto\'s trial, the three month-survival rate of the PMX-DHP group was similar to controls (61.3%, 65% respectively), but the 1 year-survival rate was significantly better in PMX-DHP group (48.2% vs. 5.9%) ([@bb0180]). However, these data should be interpreted with caution because all severe patients, such as age over 85 years, severe comorbidities, or cardiovascular instability, were excluded from the PMX-DHP group and put in the control group. Oshi et al. also reported better survival in the PMX-DHP group. They reported a 3 month and 1-year survival rate of 63% and 41.7%, respectively, in contrast to 26.1% and 9.8% in the control group. The other two studies include various types of interstitial pneumonias. Furthermore, in addition to corticosteroids, other agents, such as CTX, CsA, tacrolimus, sivelestat or anticoagulants, were administered during the study period ([@bb0210]; [@bb0280]). Itchyasu reported that among patients with AE-IPF, there was no difference in 3 month survival between PMX-DHP (40%) and control group (42.9%). However, when all types of IIP were included in the analysis, survival was better in the PMX-DHP group ([@bb0280]). Similarly, in the study by Furusawa et al., among the patients with AE-IPF, there was no difference in overall survival between the PMX-DHP (33%) and the control group (50%) ([@bb0210]). Therefore, in order to determine the effect of PMX-DHP in AE-IPF, double blind randomized controlled study is required.

Thrombomodulin {#s0140}
--------------

Thrombomodulin is a thrombin receptor on the endothelial cell surface and recombinant human thrombomodulin (rhTM) forms a reversible complex with thrombin, which activates plasma protein C and exhibits antiinflammatory, anticoagulant, and antifibrinolytic properties. Collard et al. studied the plasma biomarker profile of AE-IPF and found that mechanical ventilation and log change in thrombomodulin were both significant predictors of survival in AE-IPF ([@bb0110]). Due to the hypercoagulable state in AE-IPF, Tsushima et al. prospectively tried rhTM and reported that the 30-day survival was higher in 20 patients with AE-IPF compared to six historical controls (67% vs. 17%). Several retrospective studies using historical controls or parallel untreated controls showed promising results with a 3 month-survival rate around 60%, better than what was observed in the control group ([Table 3](#t0020){ref-type="table"}). However, they were all small studies and other medications like *N*-acetylcysteine (NAC), CTX, CsA, anticoagulants, and even PMX-DHP, were administered to the study subjects during the trial. Therefore, a Phase 3 placebo controlled randomized trial (NCT02739165) was recently performed and finished recruitment.

Antibiotics {#s0145}
-----------

Macrolides accelerate apoptosis of neutrophils and the removal of cell debris by macrophages. Azithromycin also has a modulating effect on the TH1/TH2 fate as well as the TH17/iTreg lineage (adaptive immunity) ([@bb0785]). Azithromycin inhibits the production of aberrant proinflammatory cytokines by alveolar macrophages in a dose-dependent way ([@bb0080]), suggesting a potential role in the treatment of IPF. Azithromycin was evaluated in a retrospective study and 60-day survival of 38 AE-IPF patients was significantly better (74%) compared to 47 fluoroquinolone-treated historical controls (30%, *P* \< 0.001) ([@bb0330]).

Using the Japanese Diagnosis Procedure Combination (DPC) database, Oda et al. performed a retrospective epidemiologic and prognostic analysis on 209 patients with IPF receiving mechanical ventilation and high-dose corticosteroids with or without CTX or cotrimoxazole. They found that treatments with cotrimoxazole and macrolides were significantly associated with a better prognosis and high-dose cyclophosphamide was significantly associated with a poor prognosis. The 3 months-survival rate was 24.6% and median survival time was 21 days.

Antifibrotic Drugs {#s0150}
------------------

Pirfenidone and nintedanib have been shown to reduce the progression of IPF and they may be useful in AE-IPF. Furuya et al. found that among 47 cases of AE-IPF (all treated with high dose corticosteroid and some with NAC, CTX/CsA or rhTM), the 3 month-survival rate was significantly better in 20 patients receiving pirfenidone than in 27 patients not receiving pirfenidone (55% vs. 34%, *P* = 0.042). Among the patients receiving rhTM (*N* = 22), pirfenidone did not make significant difference in the outcome (80% vs. 42%, *P* = 0.067) ([@bb0215]). In univariate analysis, nonuse of rhTM was a potential risk factor for death (hazard ratio \[HR\], 3.717; *P* = 0.035). In all patients, nonuse of pirfenidone was a potential risk factor for death (HR: 6.993; *P* = 0.043). Recently Vianello et al. reported improved median survival time of pirfenidone group (137 days) compared to nine retrospective control patients (16 days, *P*  =  0.0009) ([@bb0765]). However, the study had many limitations including a small number of the patients and older age and lower lung function in a historical control group.

Nonsteroidal Approach {#s0155}
---------------------

The PANTHER trial reported a harmful effect with the combined use of corticosteroids, NAC, and azathioprine ([@bb0585]). Therefore a nonsteroidal approach with immediate cessation of immunosuppressive therapy (if any), best supportive care and broad-spectrum antimicrobials and thorough evaluation to detect reversible causes of deterioration was tried and resulted in at least comparable survival rates (45% at 3 months and 40% in 1 year, median survival time, 1.73 month). Furthermore, a history of immunosuppressive therapy, including corticosteroids before AE, exerted a less favorable prognosis ([@bb0555]).

As reviewed above, there are no proven effective drugs for the treatment of AE-IPF, but some agents have potential and randomized controlled trials are on-going.

### Supportive care, ventilatory support {#s0160}

At present, supportive care is the mainstay of therapy in these critically ill patients, including palliation of symptoms and correction of hypoxemia with supplemental oxygen. The current IPF guidelines state that while the majority of patients with respiratory failure due to IPF should not receive mechanical ventilation, it may be a reasonable in a minority (weak recommendation, low-quality evidence) and that noninvasive ventilation (NIV) may be appropriate in some ([@bb0580]). This is based on the high in-hospital mortality observed in AE-IPF, up to 90% ([@bb0445]). Because the fibrotic noncompliant lung is more susceptible to ventilator-induced lung injury, a protective ventilation (i.e., low tidal volume) strategy, NIV ([@bb0475]; [@bb0735]; [@bb0760]), or high-flow nasal cannula oxygen ([@bb0390]; [@bb0185]) may reduce the risk. Rush et al. analyzed data from the Nationwide Inpatient Sample from the United States, and found that invasive mechanical ventilation (IMV) had a higher in-hospital mortality rate compared to NIV (51.6% with IMV vs. 30.9% in NIV, *P* \< 0.0001) among 2481 patients with IPF ([@bb0615]). In Japan, among 209 patients receiving IMV, the 30 day- and 90-day survival rates were 44.6% and 24.6%, respectively. ([@bb0530])

Lung Transplantation {#s0165}
--------------------

Lung transplantation is the last resort and is recommended by the international guidelines for highly selected patients with AE-IPF. Extracorporeal membrane oxygenation (ECMO) may be used as a bridge to transplantation as it may minimize the risk of ventilator induced lung injury and the "triggering" of fatal deterioration of the underlying fibrotic process ([@bb0470]). Recent advances in the technique has enabled ambulatory ECMO or awake, spontaneous breathing ECMO as a bridge to lung transplantation and have shown encouraging results ([@bb0220]; [@bb0240]). Because ECMO cannot reverse the original prognosis, it is appropriate to consider ECMO only for the lung transplantation candidate ([@bb0745]). Even with ECMO, the prognosis of these patients is worse than that of lung transplantation in stable IPF patients. Therefore, it is recommended that eligible patients with IPF need to have transplant evaluations early in the course of their disease, before an episode of AE-IPF.

Prognosis {#s0170}
=========

Previously, the in-hospital mortality of AE-IPF was reported to be over 50%, and in the patients on mechanical ventilation, the in-hospital mortality is 87% with an overall mortality of 94% among 135 cases reported ([@bb0445]). However, more recent studies suggest a slightly better survival, with 1 month-survival rate of 66% (range: 47--85%), 3 month rate of 41% (range: 0--54%), and survival to hospital discharge of 44% (4--77%) ([@bb0380]). For patients treated with IMV or NIV, in-hospital survival rates have been reported to be 49.4% with IMV and 69.1% with NIV, in the United States ([@bb0615]) and a 30 day-survival rate of 44.6% and 3 month-survival rate of 24.6% in Japan ([@bb0530]). The median survival of patients with IPF who experience an AE is approximately 3--4 months ([@bb0430]). Recently Aso et al. reported that the in-hospital survival rate of 7989 patients treated with CsA or high dose corticosteroids was over 70% in Japan ([@bb0050]).

Prevention {#s0175}
==========

Prevention is more effective than medical treatment of AE and avoiding triggering factors is important. Vaccination for influenza virus and Pneumococcus has been shown to be effective in preventing respiratory infection, an important triggering factor for AE. Vaccinations, along with hand washing and avoidance of sick contacts, especially in the winter season, is recommended.

GERD is another important risk factor for AE and the use of pharmacological and nonpharmacological therapy to reduce GER is an appropriate preventive measure. However, a recent study reported that antacid therapy increased the risk of overall and pulmonary infections in patients with advanced IPF (i.e., FVC \< 70%). Therefore, the risk/benefit ratio should be carefully evaluated in individual patients until a large double blinded RCT is performed.

Avoidance of airborne irritants or pollutants, and strategies to minimize mechanical ventilator-induced lung injury should be considered in patients with IPF.

Pharmacological Prophylaxis {#s0180}
===========================

Antifibrotic drugs {#s0185}
------------------

Therapies beneficial for the treatment of IPF itself may reduce the risk of AE-IPF.

### Nintedanib {#s0190}

Acute exacerbation was a key secondary endpoint in all three placebo-controlled clinical trials of nintedanib. A phase 2 trial of nintedanib in the treatment of IPF (TOMORROW) demonstrated a lower incidence of investigated-reported AE-IPF (2.4 vs. 15.7 per 100-patient years, risk ratio, 0.16, *P* = 0.02) and a delay in the time to first investigator-reported AE-IPF ([@bb0600]). In the subsequent phase 3 trials, the time to first AE-IPF was significantly delayed in INPULSIS-2 (hazard ratio: 0.38, *P* = 0.005) but not in INPULSIS-1 (hazard ratio: 1.15, *P* = 0.67) ([@bb0605]). However, a prespecified sensitivity analysis of pooled data from INPULSIS-1 and INPULSIS-2 demonstrated that nintedanib significantly delayed the time to first adjudicated AE-IPF (either confirmed or suspected) compared to placebo (hazard ratio: 0.32, *P* = 0.001). A separate pooled analysis of all three trials (TOMORROW and INPULSIS-1 and 2) demonstrated a reduction in centrally adjudicated confirmed or suspected AE-IPF with nintedanib therapy (5.9% on placebo vs. 2.2% on nintedanib, *P* = 0.01) ([@bb0125]). However, these results need to be interpreted with caution as the number of events was relatively small and no significant differences in mortality were observed between investigator reported AE, adjudicated AE and adjudicated as not-AE (other forms of acute respiratory worsening) ([@bb0125]). The time to first adjudicated AE-IPF in the prespecified pooled analysis (INPULSIS-1 and 2) and the time to first investigator-reported AE-IPF in a separate pooled analysis of all three trials (TOMORROW and INPULSIS-1 and 2) demonstrated a delay in those randomized to nintedanib.

### Pirfenidone {#s0195}

The phase 2 trial of pirfenidone performed in Japan was terminated early because of a statistically significant reduction in AE in the subjects receiving pirfenidone ([@bb0060]). Episodes of AE-IPF occurred exclusively in the placebo group (3/35 subjects) and in none of the pirfenidone group during the 9 months (*P* = 0.0031). However, a subsequent trial on 275-subjects in Japan did not replicate these results, with AE occurring in 3.6--3.7% in both the pirfenidone and control groups ([@bb0710]). The subsequent multinational phase 3 clinical trials of pirfenidone performed in Western countries (CAPACITY-1, CAPACITY-2 and ASCEND Trial) did not include AE as an end-point. Recently Ley et al. analyzed pooled data of three RCTs (2 CAPACITY and ASCEND) and found that pirfenidone was associated with a lower risk of respiratory-related hospitalization compared to placebo (7% vs. 12%, HR: 0.52; *P* = 0.001), but all-cause (HR: 0.91; *P* = 0.528) or non--respiratory-related hospitalization (HR: 1.3; *P* = 0.145) was not associated with treatment ([@bb0435]).

Pirfenidone has also been suggested to reduce the risk of AE postoperatively. Iwata et al. reported that the incidence of postsurgery AE in patients with lung cancer and IPF was lower in the pirfenidone pretreated group compared to the nontreated group (3.2% vs. 21.1%) ([@bb0295]). He also performed a phase 2 clinical trial and found reduced incidence of AE ([@bb0300]). Although these studies had several limitations, including a small number of subjects and single-arm design, it suggested a potential role for prevention with use of perioperative pirfenidone.

It is not clear whether either of these agents should be withheld or continued during an exacerbation event ([@bb0610]).

Macrolide {#s0200}
---------

Kuse et al. reported a reduced incidence of AE in patients treated with a macrolide in addition to conventional drugs (13.8%) during a 36 month follow-up period compared to patients not given a macrolide (34.8%). Further, the AE-free survival rate of the macrolide group was significantly better than the nonmacrolide group (*P* = 0.047), suggesting a potential beneficial effect of macrolide therapy on prevention of AE ([@bb0410]).

Conclusion {#s0205}
==========

With the first consensus statement in 2007 and the revised statement in 2016, AE-IPF has been better defined and progress in the knowledge about the incidence, risk factors and triggering factors has been made. The prognosis is more favorable, although it is still associated with a high-mortality rate and there is no proven effective therapy. Several new innovative therapies have been studied and suggest a potential benefit in the treatment of AE-IPF, resulting in the initiation of several double blind randomized clinical trials. Prophylactic measures are now better defined and emerging data suggest efficacy of antifibrotic drugs in the prevention of AE-IPF.

Author appreciates to Dr. Joyce Lee for reviewing and editing the manuscript.

[^1]: Patients with idiopathic clinical worsening who fail to meet all five criteria due to missing data should be termed "suspected acute exacerbations."

[^2]: If the diagnosis of idiopathic pulmonary fibrosis is not previously established this criterion can be met by the presence of radiologic and/or histopathologic changes consistent with usual interstitial pneumonia pattern on the current evaluation.

[^3]: If no previous high-resolution computed tomography is available, the qualifier "new" can be dropped.

[^4]: *BUILD*: Bosentan Use in Interstitial Lung Disease. *CAPACITY*: Clinical Studies Assessing Pirfenidone in idiopathic pulmonary fibrosis: Research of Efficacy and Safety Outcomes. *IFIGENIA*: Idiopathic Pulmonary Fibrosis International Group Exploring *N*-Acetylcysteine. *INSPIRE*: Effect of interferon gamma-1b on survival in patients with idiopathic pulmonary fibrosis. *TOMORROW*: To Improve Pulmonary Fibrosis with BIBF 1120. *STEP-IPF*: Sildenafil Trial of Exercise Performance in Idiopathic Pulmonary Fibrosis. *Y*: year.

[^5]: *AE*: acute exacerbation; *ARF*: Acute respiratory failure; *d*: day; *DL*: carbon monoxide diffusing capacity; *FVC*: forced vital capacity; *m*: month; *Pirfenidone Low dose*: 1197 mg/day; *High dose*: 2403 mg/day; *Tx*: treatment; *w*: week.

[^6]: Diagnostic criteria of acute exacerbation:

[^7]: *JRS*: Japanese Respiratory Society criteria: manifestation of all of the following: (1) worsening, otherwise unexplained clinical features within 1 month, progression of dyspnea over a few days to less than 5 weeks, (2) new radiographic/high-resolution computed tomography (HRCT) parenchymal abnormalities without pneumothorax or pleural effusion (e.g., new, superimposed ground-glass opacities), (3) a decrease in the PaO~2~ by 10 mmHg or more, and (4) exclusion of apparent infection based on absence of *Aspergillus* and Pneumococcus antibodies in blood, urine for *Legionella pneumophila*, and sputum cultures.

[^8]: IPFnet:

[^9]: \(1\) previous or concurrent diagnosis of IPF, (2) unexplained worsening or development of dyspnea within 30 days, (3) HRCT with new bilateral ground-glass opacification/consolidation, (4) no evidence of pulmonary infection by endotracheal aspirate or bronchoalveolar lavage, (5) exclusion of alternative causes.

[^10]: INPULSIS-AE criteria: all of the following criteria: (1) unexplained worsening or development of dyspnea within the previous 30 days; (2) new diffuse pulmonary infiltrates visualized on chest radiography, HRCT, or both, or the development of parenchymal abnormalities with no pneumothorax or pleural effusion (new ground-glass opacities) since the preceding visit; and (3) exclusion of any known causes of acute worsening, including infection, left heart failure, pulmonary embolism, and any identifiable cause of acute lung injury, in accordance with routine clinical practice and microbiologic studies.

[^11]: BUILD-1:

[^12]: ● AE: Not specified but the data are mentioned as acute decompensation

[^13]: ● Acute decompensation (unexplained rapid deterioration over 4 weeks with increased dyspnea requiring hospitalization and oxygen supplementation \> 5 L/min to maintain a resting oxygen saturation (arterial blood gas; SaO~2~) \> 90% or PaO~2~ \>\_55 mmHg (sea level) or 50 mmHg (above 1400 m).

[^14]: CAPACITY

[^15]: 1\) Worsening of PaO~2~ (\> 8 mmHg drop from most recent preworsening)

[^16]: 2\) Clinically significant worsening of dyspnea

[^17]: 3\) New superimposed GGO on HRCT in \> 1 lobe

[^18]: 4\) All other causes such as cardiac, thromboembolism, aspiration, or infectious processes have been ruled out.

[^19]: STEP-IPF: Acute Exacerbations

[^20]: The following three criteria will define AE in subjects with acute worsening of their respiratory conditions:

[^21]: 1\. Clinical (all of the following required): (A) Unexplained worsening of dyspnea or cough within 30 days, triggering unscheduled medical care (e.g., clinic, study visit, hospitalization); (B) No clinical suspicion or overt evidence of cardiac event, pulmonary embolism, or deep venous thrombosis to explain acute worsening of dyspnea; (C) No pneumothorax.

[^22]: 2\. Radiologic/Physiologic (only 1 of the following required): (A) New ground-glass opacity or consolidation on computed tomography (CT) scan or new alveolar opacities on chest X-ray. (B) Decline of ≥ 5% in resting room air SpO~2~ from last recorded level OR decline of ≥ 8 mmHg in resting room air PaO~2~ from last recorded level.

[^23]: 3\. Microbiologic (all of the following required): (A) No clinical evidence for infection (i.e., absence of grossly purulent sputum, fever \> 39°C orally); (B) No microbiologic evidence of infection (i.e., clinically significant bacterial growth on sputum or endotracheal aspirate cultures, quantitative culture by protected brush specimen ≥ 103 cfu/mL or bronchoalveolar lavage ≥ 104 cfu/mL or the presence of specific pathogens on stains of any of the above).

[^24]: *AZP*: azathioprine; *Azithro*: azithromycin; *Cont*: controlled; *CS*: corticosteroid; *cotrimox*: cotrimoxazol; *CTX*: cyclophosphamide; *CsA*: cyclosporine-A; *d*: day; *IIP*: idiopathic interstitial pneumonia; *LMWH*: low-molecular weight heparin; *m*: month; *multi*: multi-center; *MV*: mechanical ventilation; *Nin*: nintedanib; *NSIP*: nonspecific interstitial pneumonia; *P/F*: PaO~2~/Fraction of O~2~ in inspired air; *Pirf*: pirfenidone; *PMX*: Polymyxin B-immobilized fiber column direct hemoperfusion; *Pro*: prospective; *R*: retrospective; *rhTM*: human recombinant thrombomodulin; *S*: single center; *sivel*: sivelestat; *SR*: survival rate; *Tacro*: tacrolimus; Y: year; ±: added in some patients.

[^25]: Propensity score matched controlled study.

[^26]: Small portion of the patients were treated with PMX-DHP.

[^27]: In all 27 study subjects including the patients treated with *N*-acetyl-cysteine.
